Dana-Farber Cancer Institute: all 833 studies

Page 2 of 9. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.

• Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 2
• Li-Fraumeni & TP53 (LiFT UP): Understanding and ProgressRecruitingNCT04541654
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingNCT04468061Phase 2
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
• Serial MRI Scans During Radiation TherapyRecruitingNCT04188535Not applicable
• Stereotactic Magnetic Resonance Guided Radiation TherapyRecruitingNCT04115254Not applicable
• A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaRecruitingNCT04045470Not applicable
• Understanding Chronic Lymphocytic LeukemiaRecruitingNCT04028531
• A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
• Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell CarcinomaRecruitingNCT03875716Not applicable
• Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Enrolling by invitationNCT03689595
• Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic BiomarkersRecruitingNCT03683680Not applicable
• RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingNCT03675893Phase 2
• Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6RecruitingNCT03310879Phase 2
• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
• Hereditary Risk Factors for Thyroid CancerRecruitingNCT02747888Not applicable
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver MetastasesRecruitingNCT02172651Early Phase 1
• Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
• TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingNCT06001762Phase 2Results posted
• Insomnia Prevention in Children With Acute Lymphoblastic LeukemiaCompletedNCT05866887Not applicableResults posted
• Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell TransplantationCompletedNCT05600101Not applicableResults posted
• PROFAST Intervention in Precursor Multiple MyelomaCompletedNCT05565638Not applicableResults posted
• Sleep Treatment Education Program-1 (STEP-1)CompletedNCT05519982Not applicableResults posted
• STAMP+CBT mHealth for Cancer PainCompletedNCT05403801Not applicableResults posted
• Early Interventional Treatment for Cancer PainCompletedNCT05366413Not applicableResults posted
• Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)CompletedNCT05358951Not applicableResults posted
• Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)CompletedNCT05011279Not applicableResults posted
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results posted
• Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedNCT04899921Phase 2Results posted
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple MyelomaActive, not recruitingNCT04850846Phase 2Results posted
• Abemaciclib With or Without Atezolizumab for mCRPCCompletedNCT04751929Phase 2Results posted
• Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical ActivityCompletedNCT04717050Not applicableResults posted
• ABEMA Alone or in COMBO With MK-6482CompletedNCT04627064Phase 1Results posted
• Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results posted
• REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related FatigueCompletedNCT04525183Not applicableResults posted
• Effect of Perampanel on Peritumoral Hyperexcitability in HGGCompletedNCT04497142Phase 1/2Results posted
• RCT of CBD for Anxiety in Advanced Breast CancerActive, not recruitingNCT04482244Phase 2Results posted
• Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyCompletedNCT04479514Phase 2Results posted
• MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingNCT04425018Phase 2Results posted
• Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results posted
• Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 2Results posted
• VB-111 in Surgically Accessible Recurrent/Progressive GBMTerminatedNCT04406272Phase 2Results posted
• Cemiplimab in AlloSCT/SOT Recipients With CSCCCompletedNCT04339062Phase 1/2Results posted
• Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Videos for Advance Care Planning in Young AdultsCompletedNCT04149704Not applicableResults posted
• Palbociclib + Ganitumab In Ewing SarcomaTerminatedNCT04129151Phase 2Results posted
• Topical Tazarotene Vs Placebo In Hand-Foot-Skin ReactionsTerminatedNCT04071756Phase 2Results posted
• A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic CarcinomaCompletedNCT03999684Phase 2Results posted
• The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine FibroidsTerminatedNCT03993210Not applicableResults posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasCompletedNCT03899805Phase 2Results posted
• Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerCompletedNCT03894891Phase 2Results posted
• Individualizing Surveillance Mammography for Older Breast Cancer SurvivorsCompletedNCT03865654Not applicableResults posted
• Symptom Management Implementation of Patient Reported Outcomes in OncologyCompletedNCT03850912Not applicableResults posted
• A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active, not recruitingNCT03835819Phase 2Results posted
• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results posted
• Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled TrialCompletedNCT03783546Not applicableResults posted
• Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedNCT03777982Phase 3Results posted
• GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedNCT03765983Phase 2Results posted
• Avelumab and Radiation in Muscle-Invasive Bladder CancerTerminatedNCT03747419Phase 2Results posted
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT03717480Phase 2Results posted
• Smartphone Technology to Alleviate Malignant Pain (STAMP)CompletedNCT03717402Not applicableResults posted
• Improving Quality of Life of Prostate Cancer Survivors With Androgen DeficiencyCompletedNCT03716739Phase 2Results posted
• Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaCompletedNCT03692325Phase 2Results posted
• The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced CancerCompletedNCT03668223Not applicableResults posted
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaCompletedNCT03661723Phase 2Results posted
• Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDSCompletedNCT03660228Not applicableResults posted
• Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) InterventionCompletedNCT03638453Not applicableResults posted
• Rituximab + Immunotherapy in Follicular LymphomaTerminatedNCT03636503Phase 1Results posted
• Advance Care Planning: Promoting Effective and Aligned Communication in the ElderlyCompletedNCT03609177Not applicableResults posted
• EL CENTRO: Engaging Latinos in the Center of Cancer Treatment OptionsCompletedNCT03602885Not applicableResults posted
• ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerActive, not recruitingNCT03587740Phase 2Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• Mathematical Model-Adapted Radiation In GlioblastomaCompletedNCT03557372Not applicableResults posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal HyperplasiaTerminatedNCT03505372Not applicableResults posted
• Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisCompletedNCT03483012Phase 2Results posted
• Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic AdenocarcinomaTerminatedNCT03469258Phase 2Results posted
• MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03455764Phase 1/2Results posted
• Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCTerminatedNCT03425331Phase 2Results posted
• Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast CarcinomaActive, not recruitingNCT03422003Not applicableResults posted
• A Phase II Study of BVD-523 in Metastatic Uveal MelanomaTerminatedNCT03417739Phase 2Results posted
• Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerCompletedNCT03414684Phase 2Results posted
• BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and RenewalCompletedNCT03367247Not applicableResults posted
• Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian CancerCompletedNCT03364673Not applicableResults posted
• Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingNCT03341936Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• Pembrolizumab in Neoplasms or LymphomasSuspendedNCT03316573Phase 2Results posted
• Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results posted
• Nivolumab Plus Ipilimumab in Thyroid CancerCompletedNCT03246958Phase 2Results posted
• Shared Care: Patient-Centered Management After Hematopoietic Cell TransplantationCompletedNCT03244826Not applicableResults posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaActive, not recruitingNCT03236428Phase 2Results posted
• A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedNCT03225716Phase 1Results posted
• A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström MacroglobulinemiaCompletedNCT03187262Phase 2Results posted

← Dana-Farber Cancer Institute overview and focus areas